Type 2 diabetes mellitus+3
Not recruitingA study testing cagrilintide and semaglutide combination for kidney damage in people with chronic kidney disease and type 2 diabetes who are overweight or obese
A study testing cagrilintide and semaglutide combination for kidney damage in people with chronic kidney disease and type 2 diabetes who are overweight or obese
- Disease:Type 2 diabetes mellitusObesity+2
- Substances:CagrilintideEnalapril Maleate+3
Poland- Participants:18–64 years · 65+ years
- Substances:Cagrilintide
- Sponsor:Novo Nordisk A/S













